Alzheimer's Disease Neuroimaging Initiative 3

Completed

Conditions studied: Mild Cognitive Impairment (MCI), Alzheimer's Disease (AD)

In brief

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of Alzheimer's disease (AD). The overall goal of the study is to continue to discover, optimize, standardize, and validate clinical trial measures and biomarkers used in AD research.

Key facts

Study ID
NCT02854033
Run by
University of Southern California
People needed
1141
Starts
2016-12-02
Expected to finish
2024-05-28
Last updated by the study team
2026-03-11

Who can join

Age: 55 and older, up to 90. Sex: any. Healthy volunteers: accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.